{"entity":{"id":"nct07028424","kind":"trial","name":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","aka":["PANORAMIX"],"tldr":"A phase 2 trial of liposomal irinotecan, paclitaxel / nab-paclitaxel, gemcitabine, cAPOX (capecitabine, oxaliplatin) and other drugs in pancreatic cancer, run by GERCOR - Multidisciplinary Oncology Cooperative Group, not yet recruiting.","summary":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment is a phase 2, randomised interventional study registered as NCT07028424 by GERCOR - Multidisciplinary Oncology Cooperative Group, with a registry enrolment figure of 206 participants, started 2025-07 and due to reach its primary completion in 2029-07. Interventions recorded: Nal-IRI; Ciprofloxacin; Paclitaxel; Gemcitabine; Oxaliplatin; Leucovorin; 5-Fluorouracil; Placebo. Conditions listed: PDAC - Pancreatic Ductal Adenocarcinoma. Primary outcome: 6-month progression-free survival (PFS) rate post randomization Step 1 (R1) in Arm 1A. Sites: France. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07028424","url":"https://clinicaltrials.gov/study/NCT07028424"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["liposomal-irinotecan","paclitaxel","gemcitabine","capox","flot","fluorouracil"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07028424","phase":"2","setting":"Pancreatic Cancer First-line NALIRIFOX Optimization With 5-FU Maintenance and Role of Antibiotics and Microbiota Exploration in Second-line Treatment - A Non-comparative, Randomized Phase II PANORAMIX GERCOR G-116 PRODIGE 105 Study.","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","enrolled":206,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07028424/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}